Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV '408, which met its primary endpoint.
Teva tested a new medicine for celiac disease and the early results turned out as hoped, which made investors more interested in the company. When a medicine passes these early tests, it's a sign the company might have something valuable, but there's still a long way to go before it reaches patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.